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Abstract
Background: In recent years, there has been a huge increase in the amount of publicly-available and proprietary
information pertinent to drug discovery. However, there is a distinct lack of data mining tools available to harness
this information, and in particular for knowledge discovery across multiple information sources. At Indiana
University we have an ongoing project with Eli Lilly to develop web-service based tools for integrative mining of
chemical and biological information. In this paper, we report on the first of these tools, called WENDI (Web Engine
for Non-obvious Drug Information) that attempts to find non-obvious relationships between a query compound
and scholarly publications, biological properties, genes and diseases using multiple information sources.
Results: We have created an aggregate web service that takes a query compound as input, calls multiple web
services for computation and database search, and returns an XML file that aggregates this information. We have
also developed a client application that provides an easy-to-use interface to this web service. Both the service and
client are publicly available.
Conclusions: Initial testing indicates this tool is useful in identifying potential biological applications of compounds
that are not obvious, and in identifying corroborating and conflicting information from multiple sources. We
encourage feedback on the tool to help us refine it further. We are now developing further tools based on this
model.
Background
In common with most scientific disciplines, there has in
the last few years been a huge increase in the amount of
publicly-available and proprietary information pertinent
to drug discovery, owing to a variety of factors including
improvements in experimental technologies (High
Throughput Screening, Microarray Assays, etc),
improvements in computer technologies (particularly
the Web), funded “grand challenge” projects (such as
the Human Genome Project), an imperative to find
more treatments for more diseases in an aging popula-
tion, and various cultural shifts. This has been dubbed
data overload [1] Significant effort has therefore been
put into the development of computational methods for
exploiting this information for drug discovery, particu-
larly through the fields of Bioinformatics and Chemin-
formatics. Of particular note are the provision of
large-scale chemical and biological databases, such as
PubChem [2], ChemSpider [3], the PDB [4], and KEGG
[5], which house information about massive numbers of
compounds, proteins, sequences, assays and pathways;
the development of predictive models for biological
activity and other biological endpoints; data mining of
chemical and biological data points; the availability of
journal articles in electronic form, and associated index-
ing (such as in PubMed) and text mining of their con-
tent. Further, we are seeing an unprecedented amount
of linking of information resources, for instance with
Bio2RDF [6], Linking Open Drug Data [7] and manual
linking of database entries.
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of this information together in an intelligent way, in an
integrative fashion [8]. We can think of all these infor-
mation resources as pieces of a jigsaw, which in their
own right give us useful insights, but to get the full pic-
ture requires the pieces to be put together in the right
fashion. We thus not only need to aggregate the infor-
mation, but we also need to be able to data mine it in
an integrative fashion. There are a number of technolo-
gies that are becoming available that assist with this: in
particular, web services and Cyberinfrastructure [9]
allow straightforward, standardized interfaces to a vari-
ety of data sources and Semantic Web languages such
as XML, OWL and RDF permit the aggregation of data,
and representation of meaning and relationships in the
data respectively.
At Indiana University, we are tackling this problem
from several angles. We recently developed a Cyberin-
frastructure for cheminformatics, called ChemBioGrid,
which has made a multitude of databases and computa-
tional tools freely available for the first time to the aca-
demic community in a web service framework [10]. Of
p a r t i c u l a ri m p o r t ,w eh a v eb e e na b l et os u c c e s s f u l l y
index chemical structures in the abstracts of large num-
bers of scholarly publications through a collaboration
with the Murray Rust group at Cambridge. The infra-
structure has spurred the development of several impor-
tant client applications, including PubChemSR [11], and
the application of Web 2.0 style “mashups” using user-
scripts for a variety of life-science applications [12]. We
are continuing to support and further develop this
infrastructure.
With this infrastructure in place, we have investigated
a variety of strategies for integrating the chemical and
biological data from different sources in the infrastruc-
ture, in particular of (i) the application of data mining
techniques to chemical structure, biological activity and
gene expression data in an integrated fashion [13], (ii)
the development of a generalizable four layer model
(storage, interface, aggregation and smart client) for
integrative data mining and knowledge discovery [14],
and (iii) aggregation of web services into automatically
generated and ranked workflows [15]. We are now
investigating methods for applying these techniques on
al a r g e rs c a l e ,p a r t i c u l a r l yt ob ea b l et oe x t r a c tk n o w l -
edge from large volumes of chemical and biological data
that would not be found by searching single sources,
and to be able to use multiple independent sources to
corroborate or contradict hypotheses. To do this, we are
employing two key technologies: aggregate web services
which call multiple “atomic” web services and aggregate
the results, and Semantic Web languages for the repre-
sentation of integrated data.
In this paper we describe one of the first products of
this work, a tool called WENDI (Web Engine for Non-
obvious Drug Information) that is designed to tackle a
specific question: given a chemical compound of inter-
est, how can we probe the potential biological properties
of the compound using predictive models, databases,
and the scholarly literature? In particular, how can we
find non-obvious relationships between the compound
and assays, genes, and diseases, that cross over different
types of data source? We present WENDI as a tool for
aggregating information related to a compound to allow
these kinds of relationships to be identified.
Of course, the power of this kind of integration comes
from identifying truly non-obvious but yet real relation-
ships between these entities. Our aim in this work is to
allow a rapid differentation between known relationships
(i.e. those which a scientist with a reasonable under-
standing of the literature in a field could be expected to
already know), and unknown relationships (those which
could not be found in literature closely associated with
a field, or not part of the ‘art’ o ft h ef i e l d ) .T h e r ei s
clearly some fuzziness in this, and this makes evaluation
of a tool like WENDI for non-obviousness difficult.
However, we do present it as a useful tool based on
qualitative feedback from existing users, and we are cur-
rently devising ways of a more quantitative evaluation
(as described in the concluding section).
Implementation
1. Overall architecture
We have since extended the ChemBioGrid infrastructure
to be the primary data source for WENDI. Additionally,
for WENDI we have introduced the idea of aggregate web
services that call multiple individual, or atomic,w e bs e r -
vices and aggregate the results from these services in
XML. For example, the main web service used by
WENDI takes as input a SMILES string representing a
compound of interest, and outputs an XML file of infor-
mation about the compound aggregated by calling multi-
ple web services. This XML file can then be parsed by an
intelligent client to extract information pertinent to com-
pound properties. The overall architecture uses a four
layer approach which we described previously [14] that
includes storage, interface, aggregation and smart inter-
face layers (see Figure 1). The storage and interface layers
are implemented using the Web Service Infrastructure,
and our initial work developing aggregate web services
and smart clients comprises the work described here.
Web services either follow the Simple Object Access
Protocol (SOAP) standard [16] or REpresentational
State Transfer (RESTful) approach [17], the latter of
which are often better integrated with Hypertext Trans-
fer Protocol (HTTP) than SOAP-based services. Whilst
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marily use REST service. For example, we have created
a 3D similarity searching Web Service is based on our
local PubChem 3D database which stores 3D structures
[18] and 12 distance moments [19] for all the com-
pounds in the PubChem database. This service is called
by the WENDI web service.
Our SOAP-based services are deployed in a in Tomcat
5.5 application container, which allows us to maintain
these services easily and provides a high level of integra-
tion with our development environments, and with the
service developed by Java 1.6.0. Our Web service layer is
handled by the AXIS libraries 1.6 [20], which accept a
SOAP message, decode it to extract the relevant func-
tion arguments, call the appropriate Web service classes,
and finally encode the return value into a SOAP docu-
ment for return to the client. Our Web service is pub-
l i s h e da sW S D L[ 2 1 ]w h i c hi sa nX M L - b a s e ds t a n d a r d
for describing Web services and their parameters.
Increasingly, we are converting our services to REST for
even easier maintenance and access. A list of some of
our atomic web services can be found on the web [22]
2. Database Services
Our infrastructure contains a large number of com-
pound-related databases, including mirrors of existing
databases (such as PubChem), databases derived from
these (such as 3D structures of PubChem compounds),
and completely new databases (particularly those derived
from the literature). Our databases are housed on a
Linux server running the PostgreSQL database system,
with gNova CHORD [23] installed to allow chemical
structure searching and 2D similarity searching through
the generation of fingerprints. Mirrored databases are
updated monthly. By housing the databases in a homo-
genous environment, it is easy to perform searches that
cross multiple databases using single SQL queries, and
to routinely expose the databases with web service inter-
faces. The following databases are used in the WENDI
system:
PubChem Compound
A mirror of the PubChem Compound database, contain-
ing compound ID’s (CIDs), InChI, SMILES, compound
properties, and 166-key MACCS-style fingerprints [24]
generated by the gNova CHORD system.
PubChem Bioassay
A mirror of the PubChem Bioassay database containing
AIDs (assay ID’s), CIDs of compounds tested, and bio-
assay outcomes and scores
PubChem BioDesc
Descriptions of all PubChem bioassays
Pub3D
A similarity-searchable database of minimized 3D struc-
tures for PubChem compounds
Figure 1 Overall architecture of storage, interface, aggregation and interaction layers employed in WENDI. Each layer can be accessed
directly, or by higher layers.
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A mirror of the DrugBank dataset [25] containing CID’s
(mapping to PubChem), DBID’s( D r u g b a n kI D ’s), drug
names, SMILES, usage descriptions, and 166-key finger-
prints. The database contains nearly 4800 drug entries
including >1,350 FDA-approved small molecule drugs,
123 FDA-approved biotech (protein/peptide) drugs,
71 nutraceuticals and >3,243 experimental drugs.
MRTD
An implementation of the Maximum Recommended
Therapeutic Dose (MRTD) set [26] including name,
SMILES, and 166-key fingerprints. The database con-
tains 1,220 current prescription drugs available in
SMILES format from the FDA Web site.
Medline Chemically-aware Publications Database
PubMed IDs of papers indexed in Medline[27], with
SMILES of chemical structures (from the title and
abstract) extracted using the Oscar3 program [28]
Phenopred
a matrix of predictions of gene-disease relationships
based on known relationships mined from the literature
and machine learning predictions [29].
Comparative Toxicogenomics Database (CTD)
cross-species chemical-gene/target interactions and che-
mical-disease relationships derived from experimental
sets and the literature [30].
HuGEpedia
an encyclopedia of human genetic variation in health
and disease [31].
ChEMBL
a database of bioactive drug-like small molecules, con-
taining 2-D structures, calculated properties (e.g. logP,
Molecular Weight, Lipinski Parameters, etc.) and
abstracted bioactivities (e.g. binding constants, pharma-
cology and ADMET data) [32].
2D Tanimoto similarity searching of these datasets is
made available by the gNova CHORD tanimoto function
applied to the 2D public 166 keys, an implementation of
the popular MACCS keys. Without indexing, it runs
v e r ye f f e c t i v e l yf o ras i n g l eq u e r yo ro nas m a l ld a t a s e t ,
but the speed reduces significantly for large datasets.
We have 56,911,891 compounds in our PubChem Com-
pound table as the time of writing. To speed up the
searching, we implemented a method described by Swa-
midass & Baldi to reduce the subset of molecules that
need to be searched in similarity calculations [33]. The
method uses simple bounds on similarity that can be
applied when a similarity threshold is used (given two
fingerprints A and B, and a threshold t, we can calculate
a maximum similarity between the fingerprints as min
(a,b)/(a+b-min (a/b)), where a and b are the number of
bits set in A and B respectively).
In addition to 2D similarity searching, 3D similarity
searching is provided on Pub3D database using
12-dimensional molecular shape descriptors [20] calcu-
lated for our Pub3D database of 3D minimized struc-
tures of PubChem compounds. Similarity to a query is
calculated using Euclidean Distance. We use Post-
greSQL to store all these 12D vectors for all com-
pounds, with the CUBE type [34] extension.
3. Prediction services
We have made available a variety of predictions through
our web service framework, particularly:
￿ Tumor cell line predictions. We created 40 Ran-
dom Forest models for prediction of human tumor
cell line inhibition, trained using data from the NCI
Developmental Therapeutics Program Human
Tumor Cell Lines [13]. These predictions output a
probability of activity for a compound (0-1).
￿ Toxicity prediction. We implemented a special
modified Web service implementation of ToxTree
[35] for prediction of toxic effects
￿ Gene-disease relationships. We have implemen-
ted a table of predictions of gene-disease relation-
ships extracted from the PhenoPred tool developed
at Indiana University [29]. Also we employed the
C T Da n dH u G E p e d i ad a t at oe x p o r eg e n e - d i s e a s e
relationships,
4. Aggregate web service and client
We have created a main WENDI aggregate web service,
and a web-based client that employs the web service.
The web service takes a query SMILES string as input
(through a SOAP or REST interface), and calls a variety
of web services and database searches using the query.
Results are returned as an aggregate XML file with sec-
tions delineated according to the atomic web service
that was called. Additional XML tags are added by the
web service, in particular, Gene Ontology terms in the
PubChem Bioassay descriptions, Drug descriptions
(from Drugbank) and paper titles and abstracts, are
extracted and tagged with Gene Ontology ID’s
(GOID’s). These permit associations to be made
between genes and assays, drugs and papers.
The client permits the user to input a SMILES
string, or to draw a structure in using the JME editor
[36], and then uses JSP (Java Server Pages) to submit
the query request to the web service and display and
parse the XML results, and JavaScript to handle the
XML file as the response return back from the server
side. The layer between request submitted by the client
and response returned back from the server is effected
using AJAX (shorthand for Asynchronous JavaScript +
XML) technology. With Ajax, web applications can
retrieve data from the server asynchronously without
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page.
The primary way that the databases are employed in
WENDI is through similarity searching: finding com-
pounds in the databases that are similar to the query,
which have some known property: for example, we
retrieve compounds that are similar (>0.85 Tanimoto)
to a query molecule that are active in a given bioas-
say, are known drugs, or are referenced in a journal
article. Based on the similar property principle [37]
we can assume that these molecules are likely to have
similar properties to the query compound, thus be of
interest in understanding the potential properties of
the query.
The WENDI interface is organized into six major
sections:
Predictive models results presents the predicted prob-
ability of activity of the compound in 40 Human Tumor
Cell line assays, organized by panel type (renal, non-
small cell lung, breast, colon, etc) and color coded
according to probability of activity (red for > = 0.7, yel-
low for > = 0.6 and <0.7, and grey for <0.6). Confusion
metrics are also presented to allow the validity of these
models to be assessed. Also presented are the results of
a ToxTree analysis, particularly the classification
according to Cramer rules [38] and a breakdown of pre-
sence or absence of known toxic fragments.
Activities of similar compounds presents a list of simi-
lar compounds (Tanimoto similarity values given) in
PubChem that have been tested in bioassays, and shown
to be either active. A link to the bioassay along with the
bioassay name is given, and an additional column uses
the extraction of Gene Ontology terms from the bioas-
say description along with the PhenoPred predictions of
gene-disease relationships to list possible related dis-
eases. The DrugBank and MRTD sets are also similarity
searched with the results presented in a similar fashion;
in the case of DrugBank, drug usage descriptions are
given along with predictions of diseases extracted in a
similar way to the PubChem section
Similar compounds from chemogenomics data presents
a list of similar compounds (Tanimoto similarity values
given) from CTD, ChEMBL data that include the rela-
tionships with compounds and genes/diseases.
Similar compounds from Systems data presents a list
of similar compounds (Tanimoto similarity values given)
from KEGG data that include the relationships with
compounds and Pathways/Enzymes.
Similar compounds in the literature lists journal arti-
cles in Medline where the title or abstract contains
Figure 2 Screenshot of the results returned from WENDI for Doxorubicin.
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query. Links are given to the Journal articles
Inactivities of similar compounds presents the same
informations as Activities of similar compounds sections,
except for all of the similar PubChem compounds found
that have been tested in bioassays and shown to be
inactive.
Finally, a link is given to the raw XML file, and PDF
file for download.
Results
On submission of a query, WENDI generally returns
results within a minute. We have tested WENDI with a
variety of query compounds with known biological
activities, one of them is described below. It can be sim-
ply tested by the reader by visiting the WENDI site. As
an example, a screenshot of the first results returned for
Doxorubicin are shown in Figure 2.
Doxorubicin is an anthracyclin antibiotic that is used
primarily as a nonspecific tumor inhibitor (including
cancers of the bladder, breast, stomach, lung, ovaries,
thyroid, along with soft tissue sarcoma and multiple
myeloma). The mechanism of action is not fully under-
stood, although it is thought to be a DNA intercalator.
WENDI identifies several corroborating pieces of evi-
dence for the biological actions of Doxorubicin. In parti-
cular, it (i) predicts that the compound has a high
probability of activity in all but one of the tumor cell
line screens (red) and a medium probability in HCT-15
(colon cancer); (ii) predicts that the compounds has
toxic effects by our Toxicity prediction service, corrobo-
rated by descriptions from DrugBank; (iii) identifies spe-
cific tumor-related bioassays in which compounds
similar to Doxorubicin (and identical to it) were found
to be active (in particular, many similar compounds
w e r ef o u n dt ob ea c t i v ei nN C IT u m o rC e l lL i n e
screens, corroborating the predictions of activity); (iv)
identifies a wide variety of assays in which compounds
similar to Doxorubicin are inactive; (v) identifies several
similar drugs to Doxorubicin (Epirubcin, Daunorubicin,
Idarubicin) along with descriptions corroborating the
nonspecific anti-tumor activity; (vi) identifies numerous
publications linking Doxorubicin and related com-
pounds to a variety of tumor activities (Figure 3)
A chemical compounds recently submitted to Pub-
Chem, but not collected in our database yet, were also
used as queries for WENDI. The results and some inter-
pretations are given in the Table 1 and more results of
Figure 3 Screenshot of the insights from the literature returned from WENDI for Doxorubicin.
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Table 2.
Conclusion
In this paper, we present a integrative data mining tool
for drug discovery using aggregate web services.
WENDI aims to build a full picture of potential biologi-
cal activities of a chemical compound through the
aggregation of data from web services that represent
diverse multiple sources (including predictive models,
databases and journal articles). WENDI allows the iden-
tification of corroborating or conflicting information: for
instance, a compound might be predicted active in a
breast cancer cell line, and similar compounds might
show active in a PubChem BioAssay related to breast
cancer, or be co-located in a paper abstract with a
breast cancer related gene. We are now deveoping a
next generation of tools based on WENDI and our
recent Chem2Bio2RDF system [39] for exploring
inferred relationships between compounds and diseases,
genes, pathways using Semantic Web technologies
including ontologies and RDF. We are also devising
ways of quantitatively evaluating the extent to which
WENDI truly identifies ‘non-obvious’ kinds of relation-
ship, including using a corpus of literature in the field
as the baseline for the ‘obvious’ relationships, as well as
courting specific case studies from users for qualitative
analysis.
Availability and requirements
Project name: WENDI (Web Engine for Non-obvious
Drug Information)
Table 1 Query compounds and related biological activities retrieved from WENDI
Query CID 44246308 44246315 44247545
Reported
activities
weak activity against Sortase-A (SrtA), an
antimicrobial target
tested and shown negative for activity
against DNA polymerase alpha and beta
None
Tumor Cell Line
Predictive models
50-60% probability of activity in breast,
renal, prostate, HS, ovarian, leukemia,
melanoma, non-small cell lung; otherwise
<50% probability
50-60% probability of activity in renal,
leukemia, non-small cell lung, colon,
melanoma; otherwise <50% probability
<50% probability for all tumor cell lines
Bioassay activities
& gene
relationships of
similar
compounds
highly similar molecules found to be
antagonists of GPCR GPR7 (associated
with feeding behavior, obesity and
inflammatory pain); CYP2C9 (metabolizes
NSAIDS and sulfonylureas); inhibition of
Non small-cell lung cancer (NCI HOP-18)
and supression of colon tumors;
inhibition of HIV-1 RNase H
similar molecules are shown active in
CYP3A4 confirmation assay (important in
drug metabolism); CYP2C9 (metabolizes
NSAIDS and sulfonlyureas); BAP1
inhibition (tumor suppressor involved in
breast cancer BRCA1); probes of Alpha-
Synuclein 5’UTR (related to Parkinsons
disease); FPR (GPCR involved in
chemotaxis); antibacterial activity
(Mycobacterium tuberculosis and VIM-2
metallo-beta-lactamase)
similar compounds show activity in
CYP2C19 (metabolism of antiepeleptics
and protein-pump inhibitors); agonist of
M1 muscarinic receptor (associated with
Alzheimer’s and antipsychotics); Estrogen
receptor alpha coactivator binding
inhibitors (breast cancer association);
Bioassay inactives
of similar
compounds
many highly similar compounds
(including one with a nominal 1.0
similarity) show inactive in RNase H
screen (AID-372)
similar molecules inactive for HIV
inhibition; inhibition of breast tumors
(BRCT:pBACH1 of BRCA1); hERG inhibition;
HIV-1 RNase H inhibition; 14-3-3 protein
interaction modulators; antibacterial
(Mycobacterium tuberculosis); FKBP12
immunosupressant;
similar compounds inactive for Cdc25B
catalytic domain protein tyrosine
phosphatase; beta-glucocerebrosidase
inhibitors (linked with Gaucher disease);
14-3-3- protein interaction modulation;
hERG blockers of proarrythmic agents
CTD gene
relationships of
similar
compounds
similar compounds show link with use of
anti-inflammatory drugs (NSAIDS) in
carcinomas; CYP2C9;
similar compounds linked with Gilbert
disease; adenoma; use of anti-
inflammatory drugs (NSAIDS) in
carinomas; coronary arterial protection;
colorectal neoplasms (tumors)
None
Activities of
similar marketed
drugs
None None None
Insights from
similar
compounds in
journal articles
(MEDLINE)
None Intricatin, a similar isofavonoid, is shown
to be antimutagenic; Claussequinone has
anti-inflammatory activity
None
Interpretation Some evidence for anti-inflammatory
activity (particularly related to tumors)
and CYP2C9 inhibition; mixed evidence
on generalized anti-tumor activity and
inhibition of HIV-1 RNase H44
Generalized, nonspecific activity, although
may be worth investigating for anti-tumor
activity particularly colon cancer.
None
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matics.indiana.edu:8443/WENDI_PUBLIC/WENDI.jsp
￿ Operating system(s): Platform independent
￿ Programming language: Java
￿ Other requirements: Java browser-embedded plugin
￿ License: None. Any restrictions to use by non-
academics: None
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